RecruitingPhase 4interventionalRules rewrite

Phase 4: testing Vabysmo 6 MG in 0.05 ML Injection for Macular Degeneration, Age Related

Whose aim is to: Determine the percentage of patients with resolution of subretinal hyperreflective material (SHRM) at week 16. This study is intended to be performed in the ophthalmology departments or ophthalmology clinics of the participating sites, located in Spain.

Official registry: https://clinicaltrials.gov/study/NCT07403825 · Biobizkaia Health Research Institute · enrollment listed as 100

What this phase means

Phase 4: the treatment is already approved. This study asks new questions — longer-term effects, other diseases, or how it compares in everyday care.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Vabysmo 6 MG in 0.05 ML Injection. The registry lists allocation as na. Whose aim is to: Determine the percentage of patients with resolution of subretinal hyperreflective material (SHRM) at week 16.

They plan to enroll about 100 people at 10 sites. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

Efficacy of Faricimab in Patients With Subretinal Hyperreflective Material Associated With Type 2 or Mixed Neovascular Membranes Assessed by Multimodal Imaging

Interventions: Vabysmo 6 MG in 0.05 ML Injection

Primary outcome (registry wording): to assess the resolution of subretinal hyperreflective material (SHRM) at week 16

Who it is for (from inclusion criteria)

Ages 50 Years to any
People aged 50 and over
Diagnosed with bilateral or unilateral AMD
Eyes with SHRM and type 2 or mixed (type 1 and 2) neovascular membrane
Näive eyes treated with Faricimab following SmPC (summary of product characteristic)

Who the registry excludes

Eyes with type 1, aneurysmal type 1 and type 3 MNV
Eyes with type 2 MNV and other macular diseases (myopia, posterior uveitis, systemic diseases, such as pseudoxanthoma elasticum)
Eyes with ocular media opacity
Any neurological condition (including cognitive impairment, stroke, dementia, Parkinson, anxiety or schizophrenia) that, in the opinion of the investigator, would pose a risk to patient's safety or interfere with the assessment, procedures, or completion of the study
People who are participating or will participate in any type of clinical trial
Breastfeeding women

Contact

No central phone on the registry card. Use the official listing to reach a site.

Sites listed on ClinicalTrials.gov

10 listed

Hospital Arruzafa — Córdoba, Andalusia, Spain (recruiting)
Hospital Universitario Basurto — Bilbao, Bizkaia, Spain (recruiting)
Hospital Clínico Universitario de Valladolid — Valladolid, Castille and León, Spain (recruiting)
Hospital Universitario Nuestra Señora del Perpétuo Socorro — Albacete, Castille-La Mancha, Spain (recruiting)
Clinica Barraquer — Barcelona, Catalonia, Spain (recruiting)
Hospital Clínico San Carlos — Madrid, Madrid, Spain (recruiting)
Hospital Puerta de Hierro Majadahonda — Majadahonda, Madrid, Spain (recruiting)
Instituto Oftalmologico Fernandez-Vega — Oviedo, Principality of Asturias, Spain (recruiting)
Oftalvist Valencia — Burjassot, Valencia, Spain (recruiting)
Hospital General Universitario Valencia — Valencia, Valencia, Spain (recruiting)

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBethesda, Maryland

Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Re…

We will investigate the clinical manifestations and molecular genetic defects of heritable urologic malignant disorders. Families with urologic malignancy with known or suspected genetic basis will be enrolled.

NCT00001238 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

RecruitingNot a traditional drug phaseBethesda, Maryland

Study of Systemic Lupus Erythematosus

This protocol will evaluate patients with systemic lupus erythematosus (SLE) and their relatives to learn more about how the disease develops and changes over time. It will also study genetic factors that make a person susceptible to SLE.

NCT00001372 · Official ClinicalTrials.gov record · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

RecruitingNot a traditional drug phaseWashington D.C., District of Columbia

Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics

This study is designed to explore the genetics and pathophysiology of diseases presenting with intermittent fever, including familial Mediterranean fever, TRAPS, hyper-IgD syndrome, and related diseases. The following individuals may be eligible for this natural history study: 1) patients with known or suspected familial Mediterranean fever, TRAPS, hyper-IgD syndrome or related disorders; 2) relatives of these patients; 3) healthy, normal volunteers 7 years of age or older.

NCT00001373 · Official ClinicalTrials.gov record · National Human Genome Research Institute (NHGRI)

FAQ about this NCT record

Is NCT07403825 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07403825?

Phase 4. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07403825?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary